Torsdag 26 December | 14:24:28 Europe / Stockholm

Kalender

Tid*
2025-11-13 N/A 15-10 2025-Q3
2025-08-14 N/A Kvartalsrapport 2025-Q2
2025-05-15 N/A 15-10 2025-Q1
2025-03-21 N/A Årsstämma
2025-02-14 N/A Bokslutskommuniké 2024
2024-11-14 - 15-10 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-16 - 15-10 2024-Q1
2024-04-29 - X-dag ordinarie utdelning BRETEC 0.00 EUR
2024-04-26 - Årsstämma
2024-02-16 - Bokslutskommuniké 2023
2023-08-11 - Kvartalsrapport 2023-Q2
2023-05-26 - Årsstämma
2023-04-17 - X-dag ordinarie utdelning BRETEC 0.00 EUR
2023-02-17 - Bokslutskommuniké 2022
2022-08-12 - Kvartalsrapport 2022-Q2
2022-04-14 - X-dag ordinarie utdelning BRETEC 0.00 EUR
2022-04-13 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Bioretec är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen inkluderar exempelvis implantat för barn- och vuxenortopedi och annat material för ben- och mjukvävnadsskador. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Norden.
2022-12-08 12:00:00

Bioretec Ltd                           Press release     8 December 2022 at 1.00 p.m. EET

Bioretec Ltd, the developer and manufacturer of biodegradable orthopedic implants will participate in Inderes Life Science evening in Helsinki on 13 December 2022. At the event, the company presentation will be held by CEO Timo Lehtonen.

Further inquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493

Johanna Salko, CFO, tel. +358 40 754 8172

Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorizations are expected in U.S. during April 2023 and in Europe during 2023. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities.

Better healing - Better life. www.bioretec.com